Brokerages Anticipate G1 Therapeutics Inc (GTHX) to Post -$0.67 Earnings Per Share

Brokerages expect G1 Therapeutics Inc (NASDAQ:GTHX) to announce earnings of ($0.67) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.64) and the lowest is ($0.72). G1 Therapeutics reported earnings per share of ($0.55) in the same quarter last year, which would suggest a negative year over year growth rate of 21.8%. The company is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, November 7th.

According to Zacks, analysts expect that G1 Therapeutics will report full year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.75) to ($2.55). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.92) per share, with EPS estimates ranging from ($3.13) to ($2.72). Zacks’ EPS averages are a mean average based on a survey of research firms that cover G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.64) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.01.

Several equities analysts recently commented on the stock. BidaskClub raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC increased their price objective on shares of G1 Therapeutics to $76.00 and gave the company a “buy” rating in a research note on Tuesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $79.00 price objective on shares of G1 Therapeutics in a research note on Monday, September 17th. BTIG Research assumed coverage on shares of G1 Therapeutics in a research note on Monday, September 10th. They issued a “buy” rating and a $80.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of G1 Therapeutics from $58.00 to $63.00 and gave the company an “overweight” rating in a research note on Friday, August 10th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $74.50.

In other G1 Therapeutics news, insider Jay Strum sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of $59.60, for a total value of $596,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark A. Velleca sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $55.88, for a total transaction of $279,400.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 52,314 shares of company stock valued at $2,891,492. Corporate insiders own 15.92% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its position in G1 Therapeutics by 58.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after acquiring an additional 1,045 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in G1 Therapeutics by 44.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after acquiring an additional 1,200 shares during the period. State Board of Administration of Florida Retirement System increased its position in G1 Therapeutics by 17.5% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 8,581 shares of the company’s stock valued at $449,000 after acquiring an additional 1,280 shares during the period. Great West Life Assurance Co. Can increased its position in G1 Therapeutics by 148.3% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after acquiring an additional 1,560 shares during the period. Finally, Strs Ohio increased its position in G1 Therapeutics by 78.3% in the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after acquiring an additional 1,800 shares during the period. Hedge funds and other institutional investors own 69.09% of the company’s stock.

Shares of NASDAQ:GTHX opened at $42.72 on Wednesday. The company has a market capitalization of $1.40 billion, a P/E ratio of -11.97 and a beta of 1.16. G1 Therapeutics has a one year low of $18.03 and a one year high of $69.57.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Story: Put Option

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply